

Eribulin EMBRACE

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Eribulin EMBRACE

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: As monotherapy for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after ≥ 1 ChT regimen for advanced disease

Experimental Arm: Eribulin

Control Arm: Treatment of physician's choice

